Participated · Seed · Aug 2018

AllStripes has developed a technology platform that generates regulatory‑ready evidence and a patient application that enables patients and families to securely participate in rare disease research online. The company partners with biopharmaceutical firms, academic centers, and patient advocacy organizations to run real‑world evidence studies and support therapeutic discovery. AllStripes is a public benefit corporation and emphasizes transparent data collection and sharing across the life sciences continuum. It reports partnerships with more than 30 patient advocacy organizations across 40 conditions and is supporting more than 3,000 users to date. The platform is being expanded with enhancements to data automation, user experience, and life‑sciences offerings to improve research insights. The company plans to grow its global operational footprint and team while launching 100 new rare disease research programs. RDMD has developed an FDA-ready technology platform and a patient application that generate regulatory-grade real-world clinical evidence to accelerate research and drug development for rare diseases. The platform centralizes patient medical records and gives patients and families secure access and ownership of their data while enabling remote participation in studies. Since founding in 2018, RDMD's patient application has grown to more than 1,000 users across 12 conditions and the company has acquired patient medical information from over 1,500 hospitals. RDMD has expanded internationally to Canada and plans further expansion into Europe. The company plans to expand into 20 additional rare diseases and to be active in more than 30 conditions within a year. RDMD also reports commercial and collaborative partnerships with patient organizations, academic consortiums and biopharmaceutical customers to build regulatory-grade evidence in targeted conditions. RDMD provides an app that compiles fragmented medical records, digitizes handwritten notes and faxes via OCR, and structures the data into disease-specific timelines for patients. Patients can use the app to track treatment, get second opinions, and — if they opt in — allow their de-identified records to be used for research. RDMD sells anonymized, regulation-ready datasets to research organizations, hospitals and pharmaceutical companies to accelerate rare disease R&D. The company emphasizes producing research-grade, regulatory-grade data that can reduce time and cost in rare disease studies. RDMD has enrolled 150 patients with neurofibromatosis to date and plans to expand into additional rare diseases. The startup says collected funds will be used to build out its product and address more rare conditions. The company acknowledges privacy, security and patient trust as central operational considerations.